Shares of medical device maker Axonics Modulation Technologies (NASDAQ: AXNX) rocketed 62.7% higher in May, according to data from S&P Global Market Intelligence. This performance is even more ...

The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 28 ...

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...

Axonics Modulation Technologies Inc. Chief Executive Ray Cohen is nothing if not confident about becoming the market leader in his urology device category, despite renewed competition from medtech ...

Axonics Modulation Technologies, which is commercializing a neural implant for overactive bladder and incontinence, raised $120 million by offering 8 million shares at $15, the midpoint of the $14 to ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (“Axonics”), a medical technology company focused on the design, development and commercialization of innovative and minimally ...

* AXONICS MODULATION TECHNOLOGIES INC - MOST EMPLOYEES WILL BE TAKING TEMPORARY 20% CUT IN BASE SALARY FOR REMAINDER OF Q2 2020 DUE TO COVID-19 IMPACT Sign up here. * AXONICS MODULATION TECHNOLOGIES - ...

Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.54 per share a year ago.

This medical device stock has been on a tear since the company's Halloween 2018 IPO. Investors have been enthused about Axonics stock from the get-go, driving shares up 108% since the company's ...